Orforglipron Cuts Weight Regain to 21%-26% After GLP-1 Jabs, Undercutting $1,000 Injections
Updated
Updated · The Conversation · May 20
Orforglipron Cuts Weight Regain to 21%-26% After GLP-1 Jabs, Undercutting $1,000 Injections
4 articles · Updated · The Conversation · May 20
Trial data showed patients switched from Wegovy or Mounjaro to once-daily orforglipron regained far less weight over 52 weeks than those given placebo after stopping injections.
Among former Mounjaro users, placebo patients regained just over 50% of lost weight versus 26% on orforglipron; among former Wegovy users, regain was 62% versus 21%.
More than two-fifths of participants on the pill kept over 80% of their prior weight reduction, while blood sugar, blood pressure, insulin and cholesterol improvements also persisted.
Orforglipron is a small-molecule GLP-1 pill priced at $149-$299 a month in the US, compared with more than $1,000 for Mounjaro, though the switch trial included only a little over 100 people per group.
The drug has FDA approval for obesity in the US but is not yet licensed in the UK, where availability is expected in late 2026 to early 2027 if approved.
Can a simple genetic test soon predict if this new weight-loss pill will actually work for you?
Is a cheaper weight-loss pill the best choice if it's less effective with more side effects?
How will this breakthrough pill change the long-term fight against chronic diseases like diabetes and heart conditions?
Orforglipron and the Future of Weight Maintenance: Oral GLP-1 Therapy for Sustained Obesity Management
Overview
Orforglipron is transforming weight management by offering a once-daily oral option for people who have already lost weight with injectable incretin therapies like semaglutide or tirzepatide. This new medication addresses the common problem of weight regain after initial success, providing a crucial pathway for long-term maintenance. By focusing on sustaining health improvements over time, orforglipron marks a significant step forward beyond just losing weight. Its introduction gives patients a clinically meaningful way to preserve their weight loss and supports a shift toward more convenient, lasting solutions in obesity care.